03:20 PM EDT, 10/09/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We reduce our 12-month target price by $7 to $55, 13.5x our 2026 EPS estimate, a significant discount to BALL's five-year average forward P/E of 19.6x and aligned with competitor CCK's historical multiple, as we expect continued valuation convergence given BALL's persistent underperformance. Our 2025 and 2026 EPS estimates remain unchanged at $3.65 and $4.08, respectively. While BALL maintains a revenue growth advantage with a three-year CAGR of 4.2% vs CCK's 2.7% through 2027, this benefit is more than offset by CCK's superior margin profile, with EBITDA margins reaching 17.6% vs BALL's 16.6% by 2027. Our valuation analysis overwhelmingly favors CCK; holding variables constant, CCK offers implied returns of 25.2% vs BALL's 15.1% using P/E multiples, 48.1% vs 13.0% on EV/EBITDA metrics, and 59.5% vs -10.6% in a no-growth (2027-2031) DCF analysis. CCK's combination of defensive margin quality and superior valuation metrics outweighs BALL's revenue growth advantage, reinforcing our preference for CCK.